Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.
The Heart Failure Association of the ESC has published a clinical practice update on pharmacotherapy, procedures, devices and patient management of heart failure.
Prof. Adriaan Voors addresses 3 major questions on the future of SGLT2i in HF: on routinely use in T2DM and HF, use in HF without T2DM, and ongoing trials.
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.
The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.
ESC HF 2019 Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.
ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.
ESC HF 2019 In a post-hoc analysis of the TRANSITION trial, a higher proportion patients on target dose for sacubitril/valsartan was observed in de novo HFrEF patients compared to prior diagnosed HFrEF patients.
ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.